替米沙坦对2型糖尿病肾病患者蛋白尿的影响

Effect of Proteinuria in Patients With Type 2 Diabetic Nephropathy by Telmisartan

目的探讨替米沙坦对2型糖尿病肾病患者蛋白尿的影响。方法36例2型糖尿病肾病患者,随机平均分为替米沙坦组和洛沙坦组,在常规药物治疗的基础上,分别予替米沙坦80 mg/天及洛沙坦100 mg/天治疗,测量患者血压、24 h尿蛋白定量及生化指标。结果30周后,两组患者血压、24 h尿蛋白定量均明显下降,而血糖、血脂、肾小球滤过率(GFR)无明显变化,替米沙坦组与洛沙坦组比较,24 h尿蛋白定量下降更显著,而血压下降差别不大。结论对于2型糖尿病肾病,替米沙坦比洛沙坦有更显著降尿蛋白的作用。

Objective To investigate the effect of proteinuria of telmisartan on type 2 diabetic nephropathy. Methods In addition to ongoing treatment,thirty six type 2 diabetic patients with nephropathy were randomly devided into telmisartan group and losartan group,which were treated with telmisartan 80 mg once daily and losartan 100 mg once daily respectively,and blood pressure,24 h proteinuria and biochemical parameters were measured. Results After thirty weeks,24 h proteinuria and blood pressure decreased significantly,but blood glucose,blood-fat and glomerular filtration rate did not chang notably,in comparison with losartan group,telmisartan decreased 24 h proteinuria more significantly,but manifested a similar reduction in blood pressure. Conclusion To type 2 diabetic patients with nephropathy,telmisartan is superior to losartan in reducing proteinuria.